Rise of multidrug-resistant Streptococcus pneumoniae clones expressing non-vaccine serotypes among children following introduction of the 10-valent pneumococcal conjugate vaccine in Bulgaria

Setchanova, Lena; Alexandrova, Alexandra; Pencheva, Daniela; Sirakov, Ivo; Mihova, Kalina; Kaneva, Radka; Mitov, Ivan

doi:10.1016/j.jgar.2018.05.012

Cited by 21 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…This resistance has been especially associated with the expansion of the multidrug-resistant clone 320 documented in Colombia 20 and in other countries after the introduction of PCV10, including in Brazil, 15 Chile 16 and Bulgaria. 41 This increase in the resistance of Spn19A, together with the increase in its frequency, has led to a decrease in sensitivity to penicillin in Streptococcus pneumoniae isolates in children under 5 years of age, according to national surveillance system data. In 2008, the susceptibility to penicillin in nonmeningeal Spn isolates was 86.8%, and in 2017 it was 65.9%; a similar situation was observed with ceftriaxone, whose susceptibility in nonmeningeal strains decreased from 85.1% in 2008 to 72.9% in 2017 and with erythromycin, whose susceptibility decreased from 93% to 53.4% in the same period.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10

Moreno

Imbachi

Leal

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Introduction : With the use of pneumococcal conjugate vaccines(PCV), the behavior of invasive pneumococcal disease(IPD) has changed relative to serotype distribution. The introduction of these vaccines in national immunization programs has reduced the incidence of IPD, with a marked decrease in the circulation of the serotypes included in the vaccine used in each country. However, the subsequent emergence of other serotypes not included in the vaccine, such 19A in case of PCV7 and PCV10, has been documented. Materials and methods : This was case series study (2008–2017) in pediatric patients admitted to 10 hospitals in Bogota who were diagnosed with IPD. It was conducted during the transitional period of implementing the PCV10 vaccine in Colombia in 2012. Cases of bacteremic pneumococcal pneumonia, meningitis, primary bacteremia and osteoarticular infection were included. A descriptive analysis of the demographic, clinical and laboratory variables of patients with IPD by Spn19A, its trend over time, profiles of antimicrobial susceptibility and clinical outcomes was performed. Results : There were 463 cases of IPD, 315(68%) with known serotypes. The prevalence of IPD by Spn19A was 17.7%(56 cases), tending to increase over time. During 2008–2011, the prevalence was 4.4%, and during 2014–2017, it was 32.4%, The most frequent diagnosis was pneumonia(80.4%). In nonmeningeal isolates, 39.6% were not susceptible to penicillin. An increase in the resistance was observed over time. Conclusion : Spn19A is a prevalent cause of IPD in the pediatric population of the analyzed cohort, with an increasing trend of this serotype during the surveillance period after the introduction of PCV10, being the most common serotype identified in recent years.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10

Moreno

Imbachi

Leal

et al. 2020

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…Serotype 19 is the most prevalent pneumococcus following introduction of the 7-valent pneumococci vaccine (Isturiz et al, 2017; Koutouzis et al, 2017). Treatment of pneumococcal infections caused by antibiotic resistance strains remains a considerable challenge in clinical settings (Korona-Glowniak et al, 2018; Setchanova et al, 2018). Our results showed that ε-viniferin ( 2 ) effectively inhibited pneumococci resistant to antibiotics (clindamycin, erythromycin, and tetracycline).…”

Section: Discussionmentioning

confidence: 99%

Ruthenium Chloride—Induced Oxidative Cyclization of Trans-Resveratrol to (±)-ε-Viniferin and Antimicrobial and Antibiofilm Activity Against Streptococcus pneumoniae

et al. 2019

View full text Add to dashboard Cite

Polyphenol ε-viniferin ( 2 ) is a protective phytochemical found in several plant families. Here, we report a simple and effective method for the synthesis of (±)-ε-viniferin ( 2 ) as major product and (±)-(E)-ω-viniferin ( 3 ) as a minor product. Synthesized viniferin compounds and standard viniferin were analyzed for antibacterial and antibiofilm activity against Gram-positive bacteria Streptococcus pneumoniae . The minimum inhibitory concentrations (MICs) of (±)-ε-viniferin ( 2 ) and standard viniferin were 20 µm. However, the MICs of (±)-(E)-ω-viniferin ( 3 ) and compound 8 were 40 µm. Although viniferin significantly (p < 0.05) reduced pre-established in vitro biofilms and killed bacteria within the biofilm, it was unable to prevent biofilm formation at sub-MIC concentrations. The time kill experiment revealed that viniferin killed bacteria and reduced 2.8 log 10 bacteria at 2 × MIC concentration after 24 h. Scanning electron microscope (SEM) analysis and live/dead biofilm staining of pre-established biofilms revealed that viniferin treatment disrupts membrane integrity of biofilm bacteria. Crystal violet absorption, total protein, and DNA and RNA release revealed that viniferin alters bacterial cell permeability, eventually killing bacteria.

show abstract

“…19Aclonal complex 320, thus attention to antibiotic resistance patterns is an essential note in vaccination policies. 11 Pneumococcal vaccines are not included in Iran national immunization program, while recommended for a limited number of high-risk people. Limited data of pneumococcal serotypes from Iran is available for the last decade.…”

Section: Introductionmentioning

confidence: 99%

<p>Serotype Distribution and Antibiotic Susceptibility of <em>Streptococcus pneumoniae</em> Isolates in Tehran, Iran: A Surveillance Study</p>

Ghahfarokhi¹,

Mosadegh²,

Ahmadi³

et al. 2020

IDR

View full text Add to dashboard Cite

Introduction: Encapsulated Streptococcus pneumoniae strains cause high morbidity and mortality, mainly in countries with no pneumococcal conjugate vaccines (PCVs) immunization program. This study investigated the epidemiological changes of S. pneumoniae isolates including serotype distribution and antimicrobial susceptibility in Tehran, Iran. Methods: A total of 80 S. pneumoniae samples were collected from patients admitted to Shariati hospital over two periods. Half of the isolates were collected . The antimicrobial susceptibility testing and PCV-13 serotype coverage of S. pneumoniae isolates were evaluated among patients with invasive and non-invasive infections. Results: The most common serotypes were 23F (17.5%), 14 (16.3%), 3 (16.3%) 19F (12.5%), and 19A (12.5%) in the present study. The vaccine coverage rates of PCV-7, PCV-10 and PCV-13 were 52.6%, 52.6%, and 83.7%, respectively. S. pneumoniae isolates with the serotype of the PCV-13 showed an increasing trend during the study. Nearly half of the S. pneumoniae strains were MDR, while MDR serotype 19A increased (40%) during the study periods. A small minority of isolates (16%) belonged to non-vaccine serotypes, 65% of which were assigned to MDR. In general, the frequency of penicillin resistant and MDR strains were estimated about 27.5% and 51%, respectively. An increase was observed in resistance to erythromycin and co-trimoxazole. Conclusion: The results showed that majority of the circulating serotypes in our study are related to PCV-13 serotypes. The use of conjugate vaccine in the immunization program and surveillance of antimicrobial resistance can be effective in reducing the pneumococcal clinical burden.

show abstract

Rise of multidrug-resistant Streptococcus pneumoniae clones expressing non-vaccine serotypes among children following introduction of the 10-valent pneumococcal conjugate vaccine in Bulgaria

Cited by 21 publications

References 22 publications

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10

Emergence of Streptococcus pneumoniae serotype 19A (Spn19A) in the pediatric population in Bogotá, Colombia as the main cause of invasive pneumococcal disease after the introduction of PCV10

Ruthenium Chloride—Induced Oxidative Cyclization of Trans-Resveratrol to (±)-ε-Viniferin and Antimicrobial and Antibiofilm Activity Against Streptococcus pneumoniae

<p>Serotype Distribution and Antibiotic Susceptibility of <em>Streptococcus pneumoniae</em> Isolates in Tehran, Iran: A Surveillance Study</p>

Contact Info

Product

Resources

About